Bristol-Myers Squibb Company (BMY) Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
Bristol-Myers Squibb Company (BMY) Q1 2026 Earnings Call
Bristol-Myers Squibb Company (NYSE: BMY) Q1 2026 Earnings Conference
Bristol-Myers Squibb Company (BMY) Q1 2026 Earnings Announcement
Bristol-Myers Squibb Company (NYSE: BMY) Q1 2026 Earnings Announcement
Breaking News
BioNTech (BNTX) Reports Q4 Loss of EUR0.33/Share as COVID Vaccine Revenue Plunges; Founders Exit
BioNTech posts wider-than-expected Q4 loss of $0.33/share as COVID vaccine revenue plunges 24% year-over-year; founders to exit for new mRNA venture.
ADVERTISEMENT
Bristol-Myers Squibb Company (BMY) Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
Bristol-Myers Squibb Company (BMY) U.S. FDA Approves Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
Bristol-Myers Squibb Company (BMY) Dividend Update
Bristol-Myers Squibb Company (NYSE: BMY) Q2 2026 Dividend Update
Bristol-Myers Squibb Company (BMY) SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
ADVERTISEMENT
Bristol-Myers Squibb Company (BMY) Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
Bristol-Myers Squibb Company (BMY) TD Cowen 46th Annual Health Care Conference
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Corporate Conference